Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 1/20 | 0.44 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6985857 | 0.86 | HCRTR1 (0.51) | HCRTR1HCRTR2ABHD6DAGLA | |
| SCHEMBL3692443 | 0.85 | FABP4 (0.43) | FABP4CHRNB2CHRNB4CHRNA3HCRTR1 | |
| SCHEMBL3703633 | 0.78 | RAB9A (0.48) | FABP4 | |
| SCHEMBL3703636 | 0.78 | RAB9A (0.48) | FABP4 | |
| SCHEMBL6992853 | 0.77 | FABP4 (0.43) | FABP4HCRTR1HCRTR2LTA4HABHD6 | |
| SCHEMBL6988203 | 0.77 | FABP4 (0.51) | FABP4HCRTR1HCRTR2 | |
| SCHEMBL3700088 | 0.76 | FABP4 (0.67) | FABP4HCRTR1HCRTR2 | |
| SCHEMBL3700092 | 0.76 | FABP4 (0.67) | FABP4HCRTR1HCRTR2 | |
| SCHEMBL6989618 | 0.75 | FABP4 (0.52) | FABP4HCRTR1HCRTR2 | |
| SCHEMBL6987416 | 0.75 | FABP4 (0.43) | FABP4HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | FABP4, FABP1, FABP3 | FABP4 1/4885CHRNB1 4656/4885CHRNB2 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.